Netherton Syndrome Market Size, Share, Epidemiology, Therapies Infographic
Netherton Syndrome Market

Netherton Syndrome (NS) is a rare hereditary disorder characterized by scaling skin, hair anomalies, increased susceptibility to atopic eczema, and elevated IgE levels. Netherton Syndrome is estimated to affect 1 in 200,000 newborns. Around 150 cases were reported in medical literature, but the actual number may be much higher. Additionally, it is found to be more common in women than in men. Some of the key Netherton Syndrome symptoms include reddened skin, fragile hair shafts, babies born prematurely, trouble gaining weight, recurrent skin infections, and hypernatremia.

 

Netherton Syndrome Epidemiology Segmentation in the 7MM for the Study Period 2018-30


  • Netherton Syndrome prevalent population  
  • Netherton Syndrome severity-specific cases


Netherton Syndrome Epidemiology Epidemiology Insights Observed in 2020


  • The Netherton Syndrome prevalent population in the 7MM was found to be 3,411.
  • Among the 7MM, the highest prevalence of Netherton Syndrome was found in the United States.
  • In the EU-5 countries, Netherton Syndrome prevalent population in Germany was found to be 400, whereas Netherton Syndrome prevalent population was found to be 249 in Spain.


Netherton Syndrome Market Insight


The Netherton Syndrome Market is expected to grow at a CAGR of 11.81% during the study period 2018–2030.


Netherton Syndrome Market Drivers


  • Increasing awareness
  • Development of new therapeutic approaches


Netherton Syndrome Market Barriers


  • Fewer pipeline drugs
  • High cost associated with diagnosis


Netherton Syndrome Emerging Therapies


The emerging drugs in the Netherton Syndrome market are


  • LM-030
  • Imsidolimab
  • Ustekinumab
  • Secukinumab
  • Dupilumab, and many more


Netherton Syndrome Prominent Players


The key companies in the Netherton Syndrome market are


  • Lifemax Laboratories
  • AnaptysBio
  • Janssen Biotech, and several others.